Compass Therapeutics, Inc.
CMPX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001738021
In the last 90 days, Compass Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 215 institutions reported holding it in 13F filings for Q2 2026, worth $363.4M in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Compass Therapeutics, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 37 | 34 | −3 |
| Shares | 63.6M | 62.4M | −1.19M (−1.9%) |
| Value | $201.6M | $85.4M | −$116.3M (−57.7%) |
New holders (7)
Institutions that held Compass Therapeutics, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| CM Management, LLC | 300,000 | $411.0K | 0.35% |
| Geode Capital Management, LLC | 24,857 | $34.0K | 0.00% |
| B. Riley Wealth Management, Inc. | 14,918 | $20.0K | 0.00% |
| Renaissance Technologies LLC | 13,300 | $18.0K | 0.00% |
| Charter Oak Capital Management, LLC | 1,483 | $2.00K | 0.00% |
| Royal Bank of Canada | 783 | $1.00K | 0.00% |
| Bank of America Corp | 6 | $0 | 0.00% |
Sold out (10)
Institutions that held Compass Therapeutics, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Sphera Funds Management Ltd. | 700,000 | $2.22M |
| Driehaus Capital Management LLC | 250,000 | $793.0K |
| Octagon Capital Advisors LP | 240,000 | $761.0K |
| Citigroup Inc | 37,834 | $120.0K |
| Citadel Advisors LLC | 33,573 | $106.0K |
| New Capital Management LP | 24,243 | $77.0K |
| JPMorgan Chase & Co | 23,749 | $75.0K |
| Mirabella Financial Services LLP | 18,880 | $60.0K |
| Difesa Capital Management, LP | 10,337 | $33.0K |
| Tower Research Capital LLC (TRC) | 3,205 | $10.0K |